Rituximab-associated adverse events in nephrotic syndrome: A systematic review and meta-analysis.

ABSTRACT:

Objective

Rituximab (RTX) has been recommended to treat nephrotic syndrome (NS), but its safety has not been quantitatively analyzed.

Methods

PubMed, Embase, and the Cochrane Register of Controlled Trials databases were searched from inception to December 31, 2023, for randomized control trials (RCTs) and retrospective studies reporting the adverse events (AEs) related to RTX for treating NS. Data were expressed as odds ratios (OR) and risk difference (RD) with 95 % confidence interval (CI). Heterogeneity was identified using the Cochrane Q test and quantified by the I ² statistic.

Results

Ten RCTs and five retrospective studies with 1231 patients were enrolled. RTX significantly reduced the risk of total AEs (OR = 0.32, 95 % CI [0.13, 0.78]) compare

SUBMITTER: Yu Z 

PROVIDER: S-EPMC11745799 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature